Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Jean El Cheikh, Radwan Massoud, Basel Haffar, Elie Fares, Rami Mahfouz, Tamima Jisr, Mohamed A. Kharfan-Dabaja, Anas Mougharbel, Ali Youssef, Ali Bazarbachi & Ahmad Ibrahim. (2017) Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation. Leukemia & Lymphoma 58:11, pages 2745-2747.
Read now
Read now
Max J. Gordon, Lionel D. Lewis, Jennifer R. Brown & Alexey V. Danilov. (2017) Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities – is there an optimal dose?. Expert Review of Hematology 10:8, pages 707-718.
Read now
Read now
Ferenc Magyari, Sándor Barna, Kata Husi, Zsófia Simon, Zsófia Miltényi, László Váróczy, Miklós Udvardy & Árpád Illés. (2016) Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma. Hematology 21:7, pages 404-410.
Read now
Read now
Bruce D. Cheson, Wolfram Brugger, Gandhi Damaj, Martin Dreyling, Brad Kahl, Eva Kimby, Michinori Ogura, Eckhart Weidmann, Clemens-Martin Wendtner & Pier Luigi Zinzani. (2016) Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update. Leukemia & Lymphoma 57:4, pages 766-782.
Read now
Read now
Vijayveer Bonthapally, Hongbo Yang, Rajeev Ayyagari, Ruo-Ding Tan, Sean Cai, Eric Wu, Ashish Gautam, Andy Chi & Dirk Huebner. (2015) Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis. Current Medical Research and Opinion 31:7, pages 1377-1389.
Read now
Read now
Enrico Derenzini, Pier Luigi Zinzani & Bruce D. Cheson. (2014) Bendamustine: role and evidence in lymphoma therapy, an overview. Leukemia & Lymphoma 55:7, pages 1471-1478.
Read now
Read now
Alison Moskowitz. (2013) Bendamustine: a bridge to longer term solutions in heavily treated Hodgkin lymphoma. Leukemia & Lymphoma 54:11, pages 2339-2340.
Read now
Read now
Articles from other publishers (14)
Christopher J. Forlenza, Nitya Gulati, Audrey Mauguen, Michael J. AbsalonSharon M. Castellino, Anna Franklin, Frank G. Keller & Neerav Shukla. (2021) Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Advances 5:24, pages 5519-5524.
Crossref
Crossref
Razan Mohty, Rémy Dulery, Abdul Hamid Bazarbachi, Malvi Savani, Rama Al Hamed, Ali Bazarbachi & Mohamad Mohty. (2021) Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies. Blood Cancer Journal 11:7.
Crossref
Crossref
Stanislav Sergeevich Shklyaev, N.A. Falaleeva, T.I. Bogatyreva, A.Yu. Terekhova & M.A. Danilova. (2020) Bendamustine in the Treatment of Relapsed/Refractory Hodgkin’s Lymphoma: Literature Review and Clinical Experience. Clinical oncohematology 13:2, pages 136-149.
Crossref
Crossref
Theodoros P. Vassilakopoulos, John V. Asimakopoulos, Kostas Konstantopoulos & Maria K. Angelopoulou. (2020) Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. Therapeutic Advances in Hematology 11, pages 204062072090291.
Crossref
Crossref
Matthew Howell, Adam Gibb, John Radford & Kim Linton. (2017) Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin. British Journal of Haematology 179:5, pages 841-843.
Crossref
Crossref
Liana Nikolaenko, Robert Chen & Alex F. Herrera. (2017) Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. Therapeutic Advances in Hematology 8:10, pages 293-302.
Crossref
Crossref
G Damaj, J Cornillon, K Bouabdallah, R Gressin, S Vigouroux, T Gastinne, F Ranchon, H Ghésquières, G Salles, I Yakoub-Agha & E Gyan. (2017) Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. Bone Marrow Transplantation 52:7, pages 941-949.
Crossref
Crossref
Armando SantoroRita MazzaAlessandro PulsoniAlessandro ReMaurizio BonfichiVittorio Ruggero ZilioliFlavia SalviFrancesco MerliAntonella AnastasiaStefano LuminariGiorgia AnnechiniManuel GottiAnnalisa PeliAnna Marina LiberatiNicola Di RenzoLuca CastagnaLaura GiordanoCarmelo Carlo-Stella. (2016) Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. Journal of Clinical Oncology 34:27, pages 3293-3299.
Crossref
Crossref
Pier Luigi Zinzani, Umberto Vitolo, Simonetta Viviani, Paolo Corradini, Giovanna Motta, Monica Tani, Nicola Cascavilla, Stefan Hohaus, Francesco Merli, Lisa Argnani & Alessandro Broccoli. (2015) Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. Clinical Lymphoma Myeloma and Leukemia 15:7, pages 404-408.
Crossref
Crossref
Natalia Myakova, Nadezhda Smirnova, Dmitry Evstratov, Yulia Abugova, Dmitry Balashov, Yulia Diakonova, Dmitry Konovalov, Yulia Skvortsova & Alexey Maschan. (2015)
Brentuximab vedotin in the treatment of a patient with refractory
H
odgkin disease and
P
roteus syndrome – a case report and discussion
. Clinical Case Reports 3:7, pages 646-649.
Crossref
Crossref
Elisa Sala, Roberto Crocchiolo, Sara Gandolfi, Marta Bruno-Ventre, Stefania Bramanti, Jacopo Peccatori, Barbara Sarina, Consuelo Corti, Fabio Ciceri, Armando Santoro, Sarah Marktel & Luca Castagna. (2014) Bendamustine Combined with Donor Lymphocytes Infusion in Hodgkin's Lymphoma Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 20:9, pages 1444-1447.
Crossref
Crossref
Francesca Montanari & Catherine Diefenbach. (2014) Relapsed Hodgkin Lymphoma: Management Strategies. Current Hematologic Malignancy Reports 9:3, pages 284-293.
Crossref
Crossref
Raymond Elsoueidi, Alem Mulat & Hesham Mourad. (2014) Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient. Journal of Oncology Pharmacy Practice 20:4, pages 309-311.
Crossref
Crossref
Pier Luigi Zinzani, Enrico Derenzini, Cinzia Pellegrini, Monica Celli, Alessandro Broccoli & Lisa Argnani. (2013) Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. British Journal of Haematology 163:5, pages 681-683.
Crossref
Crossref